

2012 Symposium Program at a glance



Time	Day 1: Friday April 13	Day 2: Saturday April 14	Day 3: Sunday April 15	Day 4: Monday April 16
Breakfast Available 6am – 9am		Hot and Cold Buffet Breakfast Waterfalls Restaurant	Hot and Cold Buffet Breakfast Waterfalls Restaurant	Hot and Cold Buffet Breakfast Waterfalls Restaurant
8:00am – 9:00am		Poster Setup Daydream Island Room		
9:00am – 9:15am		Welcome Great Barrier Reef Room		
9:15am – 10:00am		Session 1: Targeting of the Androgen Receptor by novel approaches Great Barrier Reef Room	Session 7: The cutting edge of molecular pathology and drug discovery Great Barrier Reef Room	Session 13: New programs and funding opportunities – Movember Australian Survivorship Action Partnership and Global Action Plan and Prostate Cancer Canada Great Barrier Reef Room
10:00am – 10:45am		Session 2: Functions of the Androgen Receptor, androgens and anti-androgens Great Barrier Reef Room	Session 8: Provocative stress and RNA binding and DNA repair pathways to target Great Barrier Reef Room	
10:45am – 11:15am		Morning Tea Break Daydream Island Room	Morning Tea Break Daydream Island Room	Symposium concludes with Morning Tea Takeaway lunch provided for all delegates Daydream Island Room
11:15am – 12:00pm		Session 3: Things we don't think about: Challenging the dogma Great Barrier Reef Room	Session 9: Targeting metabolic pathways in advanced prostate cancer Great Barrier Reef Room	
12:00pm – 2:00pm	Symposium Registration Resort Reception Poster Set-up Daydream Island Room	Lunch & Poster Session Daydream Island Room	Lunch & Poster Session Daydream Island Room	
2:00pm – 2:45pm		Session 4: Making sense of the data: Bioinformatics – exploring the genome and data integration Great Barrier Reef Room	Session 10: Modelling prostate cancer – primary human xenografts, tissue organ culture, 3D-engineered models of bone matrices Great Barrier Reef Room	
2:45pm – 3:30pm		Session 5: Advanced imaging for preclinical development and clinical detection and therapeutic response Great Barrier Reef Room	Session 11: Preclinical development of new therapeutics Great Barrier Reef Room	
3:30pm – 4:00pm		Afternoon Tea Break Daydream Island Room	Afternoon Tea Daydream Island Room	
4:00pm – 4:45pm		Session 6: Assessing disease and treatment response from the circulation Great Barrier Reef Room	Session 12: Patterns of practice and care in prostate cancer and the associated health economics Great Barrier Reef Room	
6:00pm – 10:00pm	Welcome Dinner Sunlover's Terrace	Dinner Waterfalls Restaurant	Farewell Dinner Open Air Cinema	




Saturday 14 April 2012

Session 1: Targeting of the Androgen Receptor by novel approaches

9:15 – 10:00am

Chair



Paul Rennie

Director, Laboratory Research
Vancouver Prostate Centre
University of British Columbia

Identification of Novel Antagonists that Target Androgen Receptor Surface Sites


Speakers



Tanya Day

Research Fellow
Dame Roma Mitchell Cancer Research Centre
University of Adelaide


Deregulated androgen receptor signalling and the N-terminal domain



Lisa Butler

Senior Research Fellow, Medicine
Dame Roma Mitchell Cancer Research Centre
University of Adelaide

Targeting Hsp90-dependent maturation of the androgen receptor



Jennifer Bishop

Postdoctoral Fellow
Vancouver Prostate Centre
University of British Columbia

Combination therapy using lapatinib and MDV3100 to treat EGRF/Her2 mediated anti-androgen resistance in castration-resistant prostate cancer



Session 2: Functions of the Androgen Receptor, androgens and anti-androgens

10:00 – 10:45am

Chair



Colleen Nelson

Executive Director

Australian Prostate Cancer Research Centre – Queensland

Institute of Health and Biomedical Innovation

Queensland University of Technology

**Androgens and anti-androgens don't operate as light switch
– changing states during therapy**

Speakers



Martin Sadowski

Research Fellow

Australian Prostate Cancer Research Centre - Queensland

Institute of Health and Biomedical Innovation

Queensland University of Technology

Androgen – a double agent of prostate cancer?



Grant Buchanan

Head, Molecular Ageing Laboratory

Basil Hetzel Institute for Translational Research

University of Adelaide

Androgen receptor networks in prostatic fibroblasts



Mitchell Lawrence

Postdoctoral Fellow

Department of Anatomy and Developmental Biology

Monash University

Targeting Tumour Stroma without AR



Saturday 14 April 2012

Session 3: Things we don't think about: Challenging the dogma

11:15 – 12:00pm

Chair



Ralph Buttyan
Senior Scientist
Vancouver Prostate Centre
University of British Columbia

An Unbiased Screen Reveals and Unexpected Role for an Understudied Cell Structure in AR Activity

Speakers



Michelle Liberio
PhD Candidate
Eskitis Institute for Molecular and Cell Therapies
Griffith University

Like barnacles on a boat: Optimizing LNCaP cell culture for screening, attachment and cell behaviour



Anja Rockstroh
Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology
Cell density – tales of mystery and imagination



Barbara Lelj Garolla Di Bard
Research Associate
Department of Urology, Vancouver Prostate Centre
University of British Columbia

Using protein biophysical properties to design effective drug screening assays for the molecular chaperones HspB1



Session 4: Making sense of the data: Bioinformatics – exploring the genome and data integration

2:00 – 2:45pm

Chair



Melanie Lehman

Research Fellow

Vancouver Prostate Centre, University of British Columbia

Australian Prostate Cancer Research Centre – Queensland

Institute of Health and Biomedical Innovation, Queensland University of Technology

Genes and Genomic Complexity

Speakers



Marcel Dinger

NHMRC Research Fellow, Group Leader

Cancer Genomics and Transcriptomics Group,

Diamantina Institute for Cancer, Immunology and Metabolic Medicine

University of Queensland

Leave no base unturned: Understanding human development and disease through an integrated analysis of gene regulatory architecture




Paul Boutros

Principal Investigator

Informatics & Biocomputing Platform

Ontario Institute for Cancer Research

The Genomic Complexity of Prostate Cancer – And The Complexity of Finding It



Jacques Lapointe

Assistant Professor

Department of Surgery, Division of Urology

McGill University

Prostate cancer: from the microarray data to biomarkers and biological insights



Saturday 14 April 2012

Session 5: Advanced imaging for preclinical development and clinical detection and therapeutic response

2:45 – 3:30pm

Chair



Pamela Russell

Head of Biomedical Imaging and Prostate Cancer Models
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology

Improving Magnetic Resonance imaging strategies using nanoparticles

Speakers



Elizabeth Williams

Laboratory Head, Cancer Metastasis
Monash Institute of Medical Research
Monash University

Optical Imaging



Jason Dowling

Research Scientist, Biomedical Imaging
Australian E-Health Research Centre
Commonwealth Scientific and Industrial Research Organisation

3D anatomical models for MRI-alone prostate radiation therapy



Session 6: Assessing disease and treatment response from the circulation

4:00 – 4:45pm

Chair



Bharati Bapat

Professor

Samuel Lunenfeld Research Institute, Mt Sinai Hospital

Department of Laboratory Medicine and Pathobiology

University of Toronto

Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathological features of prostate cancer

Speakers



Carolina Soekmadji

Research Fellow

Australian Prostate Cancer Research Centre – Queensland

Institute of Health and Biomedical Innovation

Queensland University of Technology

Exosome biomarkers for castrate resistance and drug resistance prostate cancer



Jyotsna Batra

Research Fellow

Australian Prostate Cancer Research Centre – Queensland

Institute of Health and Biomedical Innovation

Queensland University of Technology

Follow up genome wide association studies in prostate cancer risk and prognosis



Chris Hovens

Scientific Director

Australian Prostate Cancer Research Centre Epworth, Victoria

Prognostic role of circulating cells in prostate cancer recurrence post surgery



Sunday 15 April 2012

Session 7: The cutting edge of molecular pathology and drug discovery

9:15 – 10:00am

Chair



Tarek Bismar

Associate Professor, Pathology and Laboratory Medicine
Oncology, Biochemistry & Molecular Biology
University of Calgary

Developing molecular signatures for aggressive and indolent prostate cancer

Speakers



Ladan Fazli

Research Pathologist, Urologic Sciences
Vancouver Prostate Centre

Gleason grading agreement between Urologic Pathologists in Active Surveillance Clinical Trial highlights problematic patterns for differentiating grade 3 from grade 4



Michael Kerger

Urological Biorepository and Data Manager
Australian Prostate Cancer Research Centre Epworth, Victoria

Profile of the Urological Biorepository: Australian Prostate Cancer Research, Victoria



Ron Quinn

Director
Eskitis Institute for Cell and Molecular Therapies
Griffith University

Multiple Approaches to New Prostate Cancer Drugs: Direct Inhibitors and Synthetic Lethal Screening using Nature Bank

Sunday 15 April 2012



Session 8: Provocative stress and RNA binding and DNA repair pathways to target

10:00 – 10:45am

Chair



Luc Furic

Research Fellow
Department of Anatomy and Development Biology
Monash University

Targeting survival signalling in prostate cancer

Speakers



Derek Richard

Head of Genomic Stability Laboratory
Institute of Health and Biomedical Innovation
Queensland University of Technology


The role of hSSB1 in maintaining genome stability



Anja Rockstroh

Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology

YB-1 – a regulator of cancer progression to castrate resistance?



Thomas Cordonnier

Postdoctoral Research Fellow
Vancouver Prostate Centre

Hsp27 is an Important Regulator of Epithelial to Mesenchymal Transition in Prostate Cancer



Sunday 15 April 2012

Session 9: Targeting metabolic pathways in advanced prostate cancer

11:15 – 12:00pm

Chair



Jeff Holst
Head, Origins of Cancer Laboratory
Centenary Institute

Coordinated control of amino acid uptake by multiple pathways in prostate cancer

Speakers



Amy Lubik
Research Fellow
Vancouver Prostate Centre

Insulin, IGF2 and ADT induced Metabolic syndrome: Pathways to prostate cancer progression



Sally Stephenson
Lecturer and Group Leader, Eph Receptor Biology Group
Institute of Health and Biomedical Innovation
Queensland University of Technology

Altered expression and cellular localisation of EphB4 in prostate cancer



Session 10: Modelling prostate cancer – primary human xenografts, tissue organ culture, 3D-engineered models of bone matrices

2:00 – 2:45pm

Chair



YZ Wang

Senior Scientist, Associate Professor
Vancouver Prostate Centre and British Columbia Cancer Agency
University of British Columbia

Lessons learned from modelling CRPC

Speakers



Lisa Butler

Senior Research Fellow, Medicine
Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide

Ex vivo culture of human prostate tissues and its utility in translational research



Dietmar Hutmacher

Professor and Chair of Regenerative Medicine
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology

Tumor Engineering Utilizing Tissue Engineering Principles



Brett Hollier

Senior Research Fellow
Australian Prostate Cancer Research Centre – Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology

Developing novel models for studying the role of EMT in Prostate Cancer Invasion and Metastasis



Sunday 15 April 2012

Session 11: Preclinical development of new therapeutics

2:45 – 3:30pm

Chair



Chris Ong
Senior Scientist
Vancouver Prostate Centre
University of British Columbia

Semaphorin 3C: a novel therapeutic target for treatment of advanced prostate cancer

Speakers



Kieran Scott
Honorary Senior Lecturer
St George Hospital Clinical School
University of New South Wales

Orally-active cyclic peptide PLA2 inhibitors



Jan Jongstra
Senior Scientist, Genetics and Development
University Health Network
Toronto Western Research Institute

PIM kinase inhibitors in combination therapies



Patrick Ling
Senior Research Fellow
Australian Prostate Cancer Research Centre - Queensland
Institute of Health and Biomedical Innovation
Queensland University of Technology

Palm oil-derived tocotrienol as the next generation anti-cancer vitamin E



Session 12: Patterns of practice and care in prostate cancer and the associated health economics

4:00 – 4:45pm

Speakers



Addie Wootten

Director of Clinical and Allied Health Research
Australian Prostate Cancer Research Centre Epworth, Victoria

Psychosocial support for men with prostate cancer



Justin Keogh

Associate Professor
Faculty of Health Sciences and Medicine
Bond University

Physical and Psychosocial Benefits of Physical Activity for Men with Prostate Cancer



Amol Wagholikar

Project Leader, Research Scientist
Australian e-Health Research Centre
Commonwealth Scientific and Industrial Research Organisation

A novel health economics model to simulate and improve advanced prostate cancer patterns of practice

Panel Discussants



Liz Hovey

Senior Staff Specialist, Medical Oncology, SESIAHS & UNSW
Prince of Wales Hospital



John Ramsay

Consultant Psychologist
Private Practice



Monday 16 April 2012

Session 13: New programs and funding opportunities

9:15 – 10:45am

Chair



Colleen Nelson


Executive Director

Australian Prostate Cancer Research Centre – Queensland

Institute of Health and Biomedical Innovation

Queensland University of Technology

Speakers



Ruth Zeisler

Consul and Senior Trade Commissioner

Consulate General of Canada

**Canadian Government, Australian-Canadian Opportunities from Canadian
Department of Foreign Affairs and International Trade and Canadian Consulate**



Stuart Edmonds

Senior Vice President, Research

Prostate Cancer Canada

Prostate Cancer Canada



Paul Villanti

Executive Director, Global Programs

Movember Foundation

Movember Survivorship Action Partnership



Mark Buzza

Global Research Program Manager

Movember Foundation

Movember Global Action Plan